Pelthos Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTHS research report →
Range $21 – $64
Price Chart
About the company
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older.
- CEO
- Scott Plesha
- IPO
- 2024
- Employees
- 92
- HQ
- Durham, NC, US
Get TickerSpark's AI analysis on PTHS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $25.08M
- P/E
- -0.36
- Fwd P/E
- 11.08
- PEG
- -0.01
- P/S
- 0.51
- P/B
- -4.15
- EV/EBITDA
- -1.42
- Div Yield
- 0.00%
- Gross Margin
- 68.23%
- Op Margin
- -101.59%
- Net Margin
- -123.24%
- ROE
- -381.40%
- ROIC
- -47.91%
Latest fiscal year · YoY change
- Revenue
- $16.80M+0.0%
- Gross Profit
- $7.43M+0.0%
- Op Income
- $-32,430,000
- Net Income
- $-43,319,000-444.5%
- EPS
- $-23.04-70.2%
- OCF Growth
- -290.0%
- FCF Growth
- -291.7%
- 52W High
- $31.62
- 52W Low
- $6.02
- 50D MA
- $16.83
- 200D MA
- $23.10
- Beta
- 3.11
- RSI (14)
- 26
- Avg Volume
- 53.72K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Pelthos posted $15.2 million of Zelsuvmi revenue in Q3, extended access coverage, and reiterated a growth story now paired with a planned Castle Creek acquisition and two additional product launches.· November 12, 2026
- Q3 Zelsuvmi net revenue was $15.2 million, up 114% year over year, and the company said it has generated $57.5 million of net product revenue since launch.
- Prescription activity kept growing: Q3 prescriptions were 12,384, up 4% sequentially and 365% year over year, with more than 10,000 unique HCP prescribers to date.
- Access improved materially in October with a major PBM agreement covering about 24 million lives and a regional formulary update covering about 3 million lives; coverage now spans 127 million commercially covered lives.
- Management said Zelsuvmi gross-to-net was 31.5% in Q3 and expects it to move into the mid-30s range as additional formulary coverage comes through.
- Pelthos is preparing Xepi for a launch by the end of Q1 2027 and Xeglyze by the end of Q3 2027, while also touting the strategic rationale of the Castle Creek deal and D-Fi rare-disease asset.
Q3 2026 net product revenue was $15.2 million, versus $15.4 million in Q2 2026 and up 114% year over year from Q3 2025. Gross-to-net was 31.5% in Q3 2026, versus 29.6% in Q2 2026. Cost of goods sold was $1.7 million, versus $3.6 million in Q2 2026; SG&A was $18.8 million, down from $25 million in Q2 2026; net loss was $7.9 million, versus $23.4 million in Q2 2026; and adjusted EBITDA was negative $5.6 million, versus negative $5.7 million in Q2 2026. Cash was $17.7 million and accounts receivable were $13.4 million as of September 30, 2026. Management did not provide formal next-quarter or full-year revenue guidance, but said it expects Zelsuvmi growth to accelerate into 2027, gross-to-net to move into the mid-30s range, Xepi to begin promotion by the end of Q1 2027, and Xeglyze to launch by the end of Q3 2027.
Scott Plesha framed the quarter as a continuation of Zelsuvmi’s commercial build, emphasizing that the company is adding prescribers, expanding coverage, and investing in long-term brand access even if that pressures gross-to-net in the near term. His tone was constructive and strategic: he repeatedly described the PBM win as a deliberate long-term investment and said the company expects more meaningful growth in 2027 and beyond. He also positioned the Castle Creek transaction as a way to evolve Pelthos into a more diversified biotech with a rare-disease asset that fits the existing dermatology commercial infrastructure.
John Gay focused on the quarter’s financial mechanics and balance sheet. He noted that Q3 net product revenue was $15.2 million, COGS was $1.7 million, SG&A was $18.8 million, net loss was $7.9 million, and adjusted EBITDA was negative $5.6 million; he also highlighted that Q2 SG&A included $5.3 million of one-time nonrecurring sales-based milestones and that Q2 COGS included a $900,000 inventory write-off. He said cash was $17.7 million at quarter-end, that the company drew an additional $10 million on the Horizon term loan after quarter-end, and that another $10 million may be available subject to conditions including trailing 12-month net revenue of at least $70 million. He also said cash basis SG&A was approximately $16.9 million in Q3 and that the company believes its current projections and financing give it flexibility to execute its plan.
Analysts pressed on Zelsuvmi’s revenue trajectory, gross-to-net direction, payer dynamics for Xepi, and the rationale for moving toward a more biotech-like model via Castle Creek. Management said the Q3 gross-to-net increase reflected a strategic PBM contract that should help growth going forward, that Xepi is seeing encouraging payer discussions because of resistance concerns around existing antibiotics, and that the company expects its current SG&A run rate to support the Xepi launch without a material increase. On Castle Creek, management repeatedly said it could not discuss all product details until the S-4 is filed, but argued D-Fi is differentiated, may be complementary to VYJUVEK, and fits Pelthos’s pediatric dermatology network and broader diversification strategy.
The bull case is that Zelsuvmi continues to show strong uptake, with over 10,000 unique prescribers, 34,000 patients treated to date, and improving access that should support future revenue. Management also pointed to October as its second-highest month ever and said the PBM win and broader formulary coverage have not yet been fully reflected in results. Beyond Zelsuvmi, Pelthos is setting up two additional launches and says the Castle Creek deal adds a potentially differentiated rare-disease asset and broader pipeline optionality.
The main risks are that Zelsuvmi revenue flattened sequentially in Q3, GTN is rising into the mid-30s range, and management is still relying on seasonal and access-driven improvements to show up over time. The company also acknowledged that the Castle Creek transaction is still in a quiet period, with limited public detail until the S-4 is filed and Phase III data still needed for D-Fi. Financially, cash was $17.7 million at quarter-end, so execution and access to the Horizon facility remain important as the company funds multiple launches and development work.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 30.7%
- Shares Outstanding
- 3.93M
- Float Shares
- 1.21M
of shares held by institutions
23 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Murchinson Ltd. | 311.02K | ▲ 6.72K |
| Ikarian Capital, LLC | 256.60K | 0 |
| Aigh Capital Management LLC | 256.01K | ▼ 73.09K |
| Boothbay Fund Management, LLC | 103.41K | ▲ 1.44K |
| Vanguard Capital Management LLC | 95.32K | ▼ 1.82K |
| Wexford Capital LP | 84.62K | ▲ 62.25K |
| Diadema Partners LP | 80.76K | ▲ 55.99K |
| Vanguard Group Inc | 75.02K | ▲ 8.18K |
| Cantor Fitzgerald, L. P. | 48.12K | ▲ 10.00K |
| Persistent Asset Partners Ltd | 20.23K | ▲ 14.22K |
| Knott David M Jr | 17.64K | ▼ 4.43K |
| Geode Capital Management, LLC | 16.57K | ▲ 1.93K |
Held by 24 ETFs
Biggest fund positions in PTHS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 2, 26 | Greenleaf Peter | sell | 797 |
| Oct 2, 26 | Friedberg Ezra M | sell | 558 |
| Oct 2, 26 | Pauls Matthew | sell | 786 |
| Jul 2, 26 | Friedberg Ezra M | sell | 534 |
| Jul 2, 26 | Friedberg Ezra M | sell | 24 |
| Jul 2, 26 | Pauls Matthew | sell | 692 |
| Jul 2, 26 | Pauls Matthew | sell | 94 |
| Jul 2, 26 | Greenleaf Peter | sell | 712 |
| Jul 2, 26 | Greenleaf Peter | sell | 85 |
| Jun 15, 26 | Friedberg Ezra M | sell | 224 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PTHS coverage
Recent articles, reports, and earnings notes.
No research on PTHS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PTHS report →Pelthos Therapeutics Inc. (PTHS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 12
Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 12
Pelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026
globenewswire.com · Nov 4
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
globenewswire.com · Oct 30
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
globenewswire.com · Oct 27
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
globenewswire.com · Oct 6
Pelthos Therapeutics Q2 Earnings Call Highlights
marketbeat.com · Aug 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.